Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-334.33	-201.59	-197.72	-143.88	-129.07
Depreciation & Amortization	0.8	0.58	0.62	0.52	0.32
Other Amortization	2.19	1.88	2.11	3.6	1.27
Stock-Based Compensation	24.05	45.03	24.13	16.81	5.84
Other Operating Activities	55.82	30.18	18.89	1.81	0.23
Change in Accounts Receivable	-37.16	-1.64	-	-	-
Change in Inventory	-6.14	-9.44	-	-	-
Change in Accounts Payable	34.94	6.41	8.68	-9.79	24.01
Change in Other Net Operating Assets	-6.93	-8.98	-3.24	-17.52	27.71
Operating Cash Flow	-266.77	-137.58	-146.53	-148.46	-69.69
Capital Expenditures	-0.14	-1.63	-1.04	-0.33	-1.04
Investing Cash Flow	-0.14	-1.63	-1.04	-0.33	-1.04
Long-Term Debt Issued	59.4	211.99	95.45	96.89	25
Total Debt Issued	59.4	211.99	95.45	96.89	25
Long-Term Debt Repaid	-	-	-	-54.13	-
Net Debt Issued (Repaid)	59.4	211.99	95.45	42.76	25
Issuance of Common Stock	123.37	155.59	24.6	1.94	89.46
Financing Cash Flow	182.77	367.58	120.04	44.71	114.46
Net Cash Flow	-84.13	228.37	-27.53	-104.08	43.73
Free Cash Flow	-266.91	-139.21	-147.57	-148.79	-70.73
Free Cash Flow Margin	-483.07%	-20412.61%	-	-	-
Free Cash Flow Per Share	-4.22	-2.71	-3.77	-4.02	-2.13
Cash Interest Paid	17.29	11.13	7.03	4.07	3.46
Levered Free Cash Flow	-203.85	-90.45	-93.78	-96.73	-22.93
Unlevered Free Cash Flow	-161.04	-66.1	-78.83	-96.08	-21.34
Change in Net Working Capital	12.33	5.5	-5.24	28.66	-52.07

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q